BioSpace News Archive

Teleflex Incorporated, a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and U.S. commercial launch of new versions of its Expro Elite and Sympro Elite Snares for manipulating interventional devices in peripheral procedures.

Mr. Walsh currently serves as the Executive Vice President and Chief Financial Officer at Catalent, a role he assumed in 2008.

In the first study1, a single LipiFlow treatment significantly improved mean meibomian gland function and significantly reduced mean dry eye signs and symptoms from baseline to three months for soft contact lens wearers with MGD, compared to those in an untreated control arm.

Results of this large, independently conducted study, published in Reviews in Urology, bring the collective published clinical utility evidence to four studies in nearly 8,300 men, demonstrating the actionable impact of the GPS test in treatment planning.

In Japan, Biocept’s patent no. 6234817 is entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION, and in Europe, Biocept’s patent no. 2995953 is entitled DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS.

The transaction is expected to be completed by February 20, 2018.

The study was established to answer the very practical, logistical questions of how a triage blood test could fit into the current Danish screening program for colorectal cancer.

In animal studies, ORC-13661 provided highly significant protection of hearing in rats exposed to high doses of aminoglycoside antibiotics, a common cause of human hearing loss.

This funding commitment from JDRF will enable Cam Med to further the development of its innovative Evopump, an ultra-thin and flexible, bandage-like patch pump.

This investment will aid in the development and clinical trials of a first-in-class drug candidate for the treatment of diabetic dry eye patients.